达格列净辅助治疗对血糖控制不佳肥胖型2型糖尿病患者胰岛功能及体重控制的影响  

Effect of Dapagliflozin Adjuvant Therapy on Islet Function and Weight Control in Obese Patients with Type 2 Diabetes Mellitus with Poor Blood Glucose Control

作　　者：黄光德 项丹丹 杨德火 HUANG Guangde;XIANG Dandan;YANG Dehuo(Department of Pharmacy,Pujiang County Traditional Chinese Medicine Hospital Zhongyu Branch,Jinhua 322200,Zhejiang,China;Department of General Clinic,Pujiang County Traditional Chinese Medicine Hospital Zhongyu Branch,Jinhua 322200,Zhejiang,China;Department of Pharmacy,Jinhua Maternal&Child Health Care Hospital,Jinhua 321000,Zhejiang,China)

机构地区：[1]浦江县中医院中余院区药剂科,浙江金华322200 [2]浦江县中医院中余院区全科门诊,浙江金华322200 [3]金华市妇幼保健院药剂科,浙江金华321000

出　　处：《糖尿病新世界》2024年第23期78-81,共4页Diabetes New World

摘　　要：目的 探讨达格列净辅助治疗对血糖控制不佳肥胖型2型糖尿病(type 2 diabetes mellitus, T2DM)患者的影响。方法 选择2023年5月-2024年5月浦江县中医院中余院区收治的160例血糖控制不佳肥胖型T2DM患者,按治疗方法的不同分为两组。对照组(80例)采用二甲双胍治疗,观察组(80例)在对照组基础上联用达格列净治疗。比较两组糖脂代谢指标、胰岛功能、体重指数(body mass index, BMI)、不良反应发生情况。结果 治疗后,观察组糖化血红蛋白、餐后2 h血糖、空腹血糖、总胆固醇、甘油三酯水平低于对照组,差异均有统计学意义(P均<0.05)。治疗后,观察组胰岛素抵抗指数、BMI低于对照组,胰岛β细胞功能指数高于对照组,差异均有统计学意义(P均<0.05)。两组不良反应发生率比较,差异无统计学意义(P>0.05)。结论 采用达格列净辅助治疗血糖控制不佳肥胖型T2DM患者,可调节血糖血脂指标,减轻体重,并可促进胰岛功能恢复,且用药安全性高。Objective To investigate the effect of dapagliflozin adjuvant therapy on obese type 2 diabetes mellitus(T2DM)patients with poor blood glucose control.Methods From May 2023 to May 2024,160 obese T2DM patients with poor blood glucose control admitted to Pujiang County Traditional Chinese Medicine Hospital Zhongyu Branch were selected and divided into two groups according to different treatment methods.The control group(80 cases)was treated with metformin,and the observation group(80 cases)was treated with dapagliflozin on the basis of the control group.The glucose and lipid metabolism indexes,islet function,body mass index(BMI)and adverse reactions were compared between the two groups.Results After treatment,the levels of glycated hemoglobin A1c,2-hour postpran-dial plasma glucose,fasting plasma glucose,total cholesterol and triglyceride in the observation group were lower than those in the control group,and the differences were statistically significant(all P<0.05).After treatment,the insulin re-sistance index and BMI of the observation group were lower than those of the control group,and the isletβcell func-tion index was higher than that of the control group,the differences were statistically significant(all P<0.05).There was no significant difference in the incidence of adverse reactions between the two groups(P>0.05).Conclusion The use of dapagliflozin in the adjuvant treatment of obese T2DM patients with poor blood glucose control can regulate blood glucose and lipid indicators,reduce body weight,promote the recovery of islet function,and have high drug safety.

关 键 词：肥胖型2型糖尿病 血糖控制不佳 达格列净 胰岛功能 体重控制 

分 类 号：R587.2[医药卫生—内分泌]